Literature DB >> 22014958

Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.

Julie K Schwarz1, Barry A Siegel, Farrokh Dehdashti, Perry W Grigsby.   

Abstract

PURPOSE: To determine the patterns of failure in patients with cervical cancer treated with definitive radiotherapy and evaluated for metabolic response with early posttherapy (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET). METHODS AND MATERIALS: The records of 238 patients with cervical cancer were reviewed. All patients were treated with a combination of external radiotherapy and intracavitary brachytherapy. Two hundred and nineteen patients (92%) received concurrent chemotherapy. All patients underwent pretreatment FDG-PET, and posttherapy FDG-PET was performed within 8-16 weeks of the completion of radiotherapy. Posttherapy FDG-PET results were categorized as complete metabolic response (CMR), partial metabolic response (PMR), and progressive disease (PD). Failure patterns were categorized as none, isolated local failure (central pelvis ± pelvic lymph nodes), distant failure, or combined local plus distant failure.
RESULTS: Of the 91 patients (38%) who had a recurrence, 22 had isolated local failures, and 69 had distant failures (49 distant failures and 20 combined local plus distant failures). Of the 173 patients with a CMR, 40 (23%) experienced treatment failure. All 25 patients with PD experienced treatment failure, which was distant in 24 patients (96%). Among the 40 patients with PMR, no failure has been observed for 14 patients (35%). Of the 26 failures within the PMR group, 15 (58%) were limited to the pelvis. Differences in the patterns of failure between the three groups (CMR, PMR, PD) were statistically significant (chi-square test; p < 0.0001).
CONCLUSIONS: The majority of failures after definitive radiotherapy for cervical cancer include distant failures, even in the setting of concurrent chemotherapy. PMR within the cervix or lymph nodes is more commonly associated with isolated local recurrence.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014958     DOI: 10.1016/j.ijrobp.2011.05.053

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  27 in total

1.  Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial.

Authors:  Feng-Yuan Liu; Chyong-Huey Lai; Lan-Yan Yang; Chun-Chieh Wang; Gigin Lin; Chee-Jen Chang; Wei-Yang Chang; Shu-Hua Huang; Yu-Erh Huang; Nan-Jing Peng; Ji-Hong Hong; Angel Chao; Hung-Hsueh Chou; Yu-Chen Chang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-10       Impact factor: 9.236

2.  ¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data.

Authors:  Shankar Siva; Siddhartha Deb; Richard J Young; Rodney J Hicks; Jason Callahan; Mathias Bressel; Linda Mileshkin; Danny Rischin; David Bernshaw; Kailash Narayan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-15       Impact factor: 9.236

3.  Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy.

Authors:  Cem Onal; Mehmet Reyhan; Ozan C Guler; Ali Fuat Yapar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

4.  Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma.

Authors:  Alexander Lin; Sirui Ma; Farrokh Dehdashti; Stephanie Markovina; Julie Schwarz; Barry Siegel; Matthew Powell; Perry Grigsby
Journal:  Int J Gynecol Cancer       Date:  2019-02-09       Impact factor: 3.437

Review 5.  Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.

Authors:  Helen Cliffe; Chirag Patel; Robin Prestwich; Andrew Scarsbrook
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

6.  Tumor radiomic heterogeneity: Multiparametric functional imaging to characterize variability and predict response following cervical cancer radiation therapy.

Authors:  Stephen R Bowen; William T C Yuh; Daniel S Hippe; Wei Wu; Savannah C Partridge; Saba Elias; Guang Jia; Zhibin Huang; George A Sandison; Dennis Nelson; Michael V Knopp; Simon S Lo; Paul E Kinahan; Nina A Mayr
Journal:  J Magn Reson Imaging       Date:  2017-10-16       Impact factor: 4.813

7.  Changes in cervical cancer FDG uptake during chemoradiation and association with response.

Authors:  Elizabeth A Kidd; Maria Thomas; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-18       Impact factor: 7.038

8.  Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors:  Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader
Journal:  Gynecol Oncol       Date:  2013-04-13       Impact factor: 5.482

9.  A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy.

Authors:  Kung-Chu Ho; Yu-Hua Dean Fang; Hsiao-Wen Chung; Tzu-Chen Yen; Tsung-Ying Ho; Hung-Hsueh Chou; Ji-Hong Hong; Yi-Ting Huang; Chun-Chieh Wang; Chyong-Huey Lai
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-07-06

Review 10.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.